Supplementary Figure 1 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Fabio Girardi(London School of Hygiene & Tropical Medicine), Rita De Sanctis(Humanitas University), Alberto Zambelli, Valentina Guarneri(Istituto Oncologico Veneto), Marcello Lo Mele(University of Padua), Giovanni Zarrilli(University of Padua), Alessandra Bisagni(Ospedale Santa Maria), Francesca Porra(University of Padua), Matteo Fassan(University of Padua), Giancarlo Bisagni, Mariangela Gaudio(Humanitas University), Leocadia Dore(Humanitas University), Bethania Fernandes(Humanitas University), Giacomo Santandrea(Azienda Sanitaria Unità Locale di Reggio Emilia), Michele Bottosso(University of Padua), Moira Ragazzi(Santa Maria Nuova Hospital), Davide Massa(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Daniela Iannaccone(University of Padua)
Cited by 0
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Sustainable care for children with cancer: a Lancet Oncology Commission
|The Lancet Oncology|2020|346
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290